Table 3.
Association of ABCG2 Polymorphism with Clinical Characteristics
| CC No. (%) | CA+AA No. (%) | P value | |
|---|---|---|---|
| Age (years) | 0.453 | ||
| Median (range) | 58 (24–87) | 58 (30–83) | |
| Race | |||
| White | 368 (79.8) | 93 (20.2) | 0.912 |
| Black | 20 (87.0) | 3 (13.0) | |
| Other | 16 (72.7) | 6 (27.3) | |
| Performance Status | |||
| 0 | 194 (80.2) | 48 (19.8) | 0.232 |
| 1 | 191 (80.9) | 45 (19.1) | |
| 2 | 19 (67.9) | 9 (32.1) | |
| Stage/Debulking | 0.654 | ||
| Stage III – microscopic | 125 (82.2) | 27 (17.8) | |
| Stage III – optimal | 185 (79.7) | 47 (20.3) | |
| Stage III – suboptimal | 57 (79.2) | 15 (20.8) | |
| Stage IV | 37 (74.0) | 13 (26.0) | |
| Histology | |||
| Serous | 314 (79.9) | 79 (20.1) | 0.715 |
| Endometrioid | 27 (73.0) | 10 (27.0) | |
| Clear cell | 18 (78.3) | 5 (21.7) | |
| Mucinous | 3 (100) | 0 (0) | |
| Others | 42 (84.0) | 8 (16.0) | |
| Tumor Grade | |||
| 1 | 38 (82.6) | 8 (17.4) | 0.774 |
| 2 | 145 (78.4) | 40 (21.6) | |
| 3 | 221 (80.4) | 54 (19.6) |